The unmet need for COVID-19 treatment in immunocompromised patients
Abstract Background Immunocompromised (IC) patients are at increased risk of severe and/or prolonged COVID-19. Main text The recent study by Scaglione et al., addresses the issue of IC outpatients with SARS-CoV-2 infection. Authors describe the real-life use of SARS-CoV-2 antivirals and/or monoclona...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-12-01
|
| Series: | BMC Infectious Diseases |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12879-022-07918-x |
| _version_ | 1798005408530432000 |
|---|---|
| author | D’Abramo Alessandra Vita Serena Nicastri Emanuele |
| author_facet | D’Abramo Alessandra Vita Serena Nicastri Emanuele |
| author_sort | D’Abramo Alessandra |
| collection | DOAJ |
| description | Abstract Background Immunocompromised (IC) patients are at increased risk of severe and/or prolonged COVID-19. Main text The recent study by Scaglione et al., addresses the issue of IC outpatients with SARS-CoV-2 infection. Authors describe the real-life use of SARS-CoV-2 antivirals and/or monoclonal antibodies and the clinical benefit in high-risk COVID-19 patients. The study supports the use of early combination therapy in a subgroup of extremely high risk patients, and considers the combined strategy as a gold standard regimen to both increase the effectiveness of early treatment, especially in IC individuals, and, reduce the emergence of SARS-CoV-2 escape mutants. Conclusion A tailored and standardised therapeutic approach in case of IC out and inpatients with SARS-CoV-2 infection is needed. |
| first_indexed | 2024-04-11T12:38:58Z |
| format | Article |
| id | doaj.art-821b9482261143c69727c778b2636c3f |
| institution | Directory Open Access Journal |
| issn | 1471-2334 |
| language | English |
| last_indexed | 2024-04-11T12:38:58Z |
| publishDate | 2022-12-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Infectious Diseases |
| spelling | doaj.art-821b9482261143c69727c778b2636c3f2022-12-22T04:23:33ZengBMCBMC Infectious Diseases1471-23342022-12-012211310.1186/s12879-022-07918-xThe unmet need for COVID-19 treatment in immunocompromised patientsD’Abramo Alessandra0Vita Serena1Nicastri Emanuele2National Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCSNational Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCSNational Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCSAbstract Background Immunocompromised (IC) patients are at increased risk of severe and/or prolonged COVID-19. Main text The recent study by Scaglione et al., addresses the issue of IC outpatients with SARS-CoV-2 infection. Authors describe the real-life use of SARS-CoV-2 antivirals and/or monoclonal antibodies and the clinical benefit in high-risk COVID-19 patients. The study supports the use of early combination therapy in a subgroup of extremely high risk patients, and considers the combined strategy as a gold standard regimen to both increase the effectiveness of early treatment, especially in IC individuals, and, reduce the emergence of SARS-CoV-2 escape mutants. Conclusion A tailored and standardised therapeutic approach in case of IC out and inpatients with SARS-CoV-2 infection is needed.https://doi.org/10.1186/s12879-022-07918-xImmunocompromised patientsSevere and/or prolonged COVID-19Passive immunotherapyAntiviral therapyCombined therapy |
| spellingShingle | D’Abramo Alessandra Vita Serena Nicastri Emanuele The unmet need for COVID-19 treatment in immunocompromised patients BMC Infectious Diseases Immunocompromised patients Severe and/or prolonged COVID-19 Passive immunotherapy Antiviral therapy Combined therapy |
| title | The unmet need for COVID-19 treatment in immunocompromised patients |
| title_full | The unmet need for COVID-19 treatment in immunocompromised patients |
| title_fullStr | The unmet need for COVID-19 treatment in immunocompromised patients |
| title_full_unstemmed | The unmet need for COVID-19 treatment in immunocompromised patients |
| title_short | The unmet need for COVID-19 treatment in immunocompromised patients |
| title_sort | unmet need for covid 19 treatment in immunocompromised patients |
| topic | Immunocompromised patients Severe and/or prolonged COVID-19 Passive immunotherapy Antiviral therapy Combined therapy |
| url | https://doi.org/10.1186/s12879-022-07918-x |
| work_keys_str_mv | AT dabramoalessandra theunmetneedforcovid19treatmentinimmunocompromisedpatients AT vitaserena theunmetneedforcovid19treatmentinimmunocompromisedpatients AT nicastriemanuele theunmetneedforcovid19treatmentinimmunocompromisedpatients AT dabramoalessandra unmetneedforcovid19treatmentinimmunocompromisedpatients AT vitaserena unmetneedforcovid19treatmentinimmunocompromisedpatients AT nicastriemanuele unmetneedforcovid19treatmentinimmunocompromisedpatients |